| 000 | 01623 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515014937.0 | ||
| 264 | 0 | _c20060323 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a0094-6354 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aO'Sullivan, Joseph | |
| 245 | 0 | 0 |
_aMigraine development, treatments, research advances, and anesthesia implications. _h[electronic resource] |
| 260 |
_bAANA journal _cFeb 2006 |
||
| 300 |
_a61-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Distribution |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 |
_aAnalgesics, Opioid _xtherapeutic use |
| 650 | 0 | 4 |
_aAnesthesia _xmethods |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use |
| 650 | 0 | 4 |
_aCalcitonin Gene-Related Peptide _xantagonists & inhibitors |
| 650 | 0 | 4 | _aCortical Spreading Depression |
| 650 | 0 | 4 |
_aErgotamine _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMigraine Disorders _xdiagnosis |
| 650 | 0 | 4 |
_aNurse Anesthetists _xorganization & administration |
| 650 | 0 | 4 |
_aPeptides _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 |
_aPrimary Prevention _xmethods |
| 650 | 0 | 4 |
_aQuinazolines _xpharmacology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSerotonin Receptor Agonists _xtherapeutic use |
| 650 | 0 | 4 | _aSex Distribution |
| 650 | 0 | 4 |
_aTrigeminal Nerve _xphysiopathology |
| 700 | 1 | _aMcCabe, Joseph T | |
| 773 | 0 |
_tAANA journal _gvol. 74 _gno. 1 _gp. 61-9 |
|
| 999 |
_c16094738 _d16094738 |
||